chromatographed sequentially to enrich for BRCA2-
Affinity-Purification Recently, a report using in vitro transactivation assays of a BRCA2-Containing Complex has suggested a role for the amino-terminal domain of To determine the polypeptide composition of BRCA2-containing complex(es), HeLa nuclear or S100 (a side fraction of nuclear extract preparation) extracts were § To whom correspondence should be addressed (e-mail: shiekhattar@ wistar.upenn.edu).
chromatographed sequentially to enrich for BRCA2- containing complex(es) (Figure 1a) . Analysis of these tained (Figure 1c ). Blast analysis using BRAF35 as query identified a second human open reading frame with extenfractions by gel filtration chromatography revealed that BRCA2 was a component of a 2 MDa complex (data not sive homology to BRAF35, designated iBRAF35 (imitation BRAF35). This analysis also revealed Mus musculus Droshown). To purify this complex, DEAE-Sephacel fractions were subjected to affinity-purification using monosophila melanogaster and Caenorhabditis elegans homolog of BRAF35 (Figure 1d ). and polyclonal anti-BRCA2 antibodies (Marmorstein et al., 1998). Western blot analysis of the affinity-eluates Analysis of the predicted sequence of human BRAF35 indicated that it encodes a protein containing a single confirmed the presence of BRCA2 protein (data not shown). However, the yields for the BRCA2 protein were sequence nonspecific HMG domain and a region with two heptad repeats similar to the coiled-coil region of variable in different preparations, as it could not be efficiently eluted from the affinity matrix. Polypeptides spekinesin. Interestingly, the only other protein with similar structural domains to BRAF35 is BAF57, a subunit of cifically eluted from the BRCA2 affinity matrix ( Figure  1b) were analyzed by matrix-assisted laser desorption/ the human SWI/SNF complex (Wang et al., 1998 To confirm the association of BRAF35 and BRCA2, we employed several approaches. We purified the BRCA2 tags containing the full-length BRAF35 protein were ob- To determine the number of BRAF35-containing comthroughout the purification scheme (Figures 2b and 2c) . Analysis of the BRAF35/BRCA2 complex on the last plexes, we followed BRAF35 immunoreactivity following the chromatographic scheme presented in Figure 3a . chromatograpic step revealed the precise coelution of BRCA2 and BRAF35 as components of a large multiproAnalysis of Superose 6 gel filteration revealed two peaks of immunoreactivity for BRAF35. A complex of approxitein ‫2ف(‬ MDa) complex (Figure 2c ). We then used anti-BRCA2 antibodies to specifically precipitate BRAF35 mately 2 MDa that contains BRCA2 eluted with a sharp peak in fraction 18 and a second smaller BRAF35 comfrom HeLa nuclear extract (Figure 2d) . Based on the known ability of these antibodies to enrich for BRCA2 plex (approximately 500 kDa) lacking BRCA2 ( Figure  3a ) eluting in fractions 26-30. Therefore, BRAF35 is a (around 5%-10% efficiency), we estimate that at least 2%-4% of endogenous BRAF35 was present in BRCA2 component of at least two complexes displaying different molecular sizes. complex(es). Furthermore, the inability of the C-terminal anti-BRCA2 antibodies to immunoprecipitate BRAF35
To determine whether BRAF35 can directly interact with BRCA2, we performed protein-protein interaction from Capan-1 nuclear extract (containing a truncated BRCA2 protein, Goggins et al. 
BRAF35 Decorates the Early Mitotic Chromosomes during Initiation of Mitotic Chromosome Condensation
To directly assess the role of BRAF35 in mitotic cells, was resolved using a linear 10 column volume gradient of 700 to 0 mM NH 4 SO 4 in buffer HB. BRCA2-containing fractions were dialyzed to 10 mM K x PO 4 in buffer HA (5 mM Hepes, pH 7.6, 1 mM dithiothreiExperimental Procedures tol, 0.5 mM PMSF, 10 M CaCl 2 , 10% glycerol, 40 mM KCl, 1 g/ ml aprotinin, 1 g/ml leupeptin, and 1 g/ml pepstatin) and loaded Affinity Purification of BRCA2 from Nuclear or S100 Extract Affinity purification of BRCA2-associated polypeptides was peron a BioScale CHT5-I column (BioRad). The column was resolved using a linear 15 column volume gradient of 10 to 600 mM K x PO 4 formed using either mono-or polyclonal anti-BRCA2 antibodies (Marmorstein et al., 1998). Antibodies were coupled to 1 ml protein in buffer HA. Fractions containing BRCA2 were dialyzed to 100 mM KCl in buffer A containing 1 g/ml aprotinin, leupeptin, and A agarose beads (Repligen) as described (Harlow and Lane, 1988). The resin was incubated overnight at 4ЊC with 10 mg HeLa DEAEpepstatin, and loaded on Heparine-5PW (TosoHaas). The column was resolved using a linear 20 column volume gradient of 100 to Sephacel precleared with 1 ml protein A beads. Binding was carried out in NEBB buffer (250 mM NaCl, 30 mM Tris 7.6, 10% glycerol, 450 mM KCl in buffer A containing 1 g/ml aprotinin, leupeptin, and Immunofluorescence experiments were performed using monocolumn (Pharmacia). The column was resolved using a linear 10 clonal and polyclonal antibodies against BRCA2 and BRAF35 as column volume gradient of 100 to 650 mM KCl. Fractions containing described (Yarden and Brody, 1999) . For experiments shown in BRCA2 (500 mM KCl, 0.5 mg) were dialyzed to 700 mM KCl, 0.1% Figure 6 , cells grown on coverslips were washed with ice-cold PBS NP-40 in buffer A and loaded on a Superose 6 HR 10/30 (Pharmacia) twice, then treated with ice-cold cytoskeleton buffer containing: 10 equilibrated in the same buffer containing 1 g/ml aprotinin, leupepmM PIPES pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 1 tin, and pepstatin. mM EGTA, 0.5% triton X-100. After 5 min on ice, cells were aspirated and were treated with ice-cold stripping buffer containing: 10 mM Monoclonal anti-BRCA2 antibodies (4.56 and 5.23) were raised with 150 mM NaCl, 500 mM NaCl, and 150 mM NaCl in Buffer G. Approximately 10 g of overexpressed E.coli BRAF35 (pET-28b, against a BRCA2 fusion protein encoding amino acids 2959-3418. We also developed monoclonal antibodies (4.21) to a BRAF35 fusion Novagen) lysate was added and beads were incubated for 3 hr at 4ЊC. Beads were washed two times each with 300 mM NaCl, and protein (amino acids 103-317) using The Wistar Institute Hybridoma Facility. Polyclonal antibodies were also developed against the last 150 mM NaCl in Buffer G, and eluted with 30 mM glutathione plus 150 mM NaCl in Buffer G. Samples were subjected to SDS-PAGE twenty amino acids of BRCA2 (C20) and BRAF35 and the first twenty amino acid of BRAF35 (Poly (N)). All polyclonal antibodies were followed by Western blotting to determine the presence of BRAF35. affinity purified using the appropriate peptides. Antibodies against phosphorylated S10 and S28 were purchased through UBI and Antibody Microinjection Experiments Hela cells plated on No. 1 coverslips were synchronized by a double Sigma, respectively. thymidine block. Rabbit anti-BRCA2, BRAF35, and nonimmune antibodies were concentrated to ‫5ف‬ mg/ml in PBS and injected into GST-BRCA2 Fusion Proteins and GST Pull-Down Experiments nuclei of cells 30 to 60 min following release form the block using an Eppendorf semi-automated microinjector and manipulator mounted GST-BRCA2 fusion protein constructs were a gift from F. J. Couch. GST-BRCA2 fusion proteins #1 to #7 correspond to amino acids on a Nikon TE300 inverted microscope. Samples were taken at approximately 12 to 14 hr after release from the G1/S boundary 195-784, 705-1217, 1171-1658, 1648-2190, 2114-2608, 2634-2999, and 2959-3418, respectively. GST and GST-BRCA2 (pGEX, Amerwhen neighboring uninjected cells or cells injected with nonimmune IgG had mostly exited mitosis. Cells were fixed in 3.7% paraformalsham Pharmacia) fusion proteins were expressed in E. coli BL21. Cells were harvested and lysed by sonicating in 150 mM NaCl in dehyde/PBS for 8 min, permeabilized in 0.2% Triton X-100/PBS/ 0.1% BSA for 5 min, washed in PBS/0.1% BSA, and stained. Injected Buffer G (50 mM Tris, pH 8.0, 10% glycerol, 0.5% Triton X-100, 0.5 mM PMSF, 1 g/ml aprotinin, 1 g/ml leupeptin, and 1 g/ml pepantibodies were detected with FITC anti-rabbit secondary antibodies (Jackson Immunoresearch). Cells were also costained with VD statin). The cell lysates were cleared by centrifugation (105,000 ϫ g for 60 min at 4ЊC). Concentration of GST or GST-BRCA2 fusion human autoimmune serum to detect CENP-F (Rattner et al., 1993), rat anti-phospho Ser-10 H3, and visualized with Cy5 conjugated proteins in cell lysates was determined by estimation of protein concentration by Coomassie staining of SDS-PAGE samples purianti-human (Jackson Immunoresearch) and Alexa594 conjugated anti-rat secondary antibodies (Molecular Probes), respectively. Covfied by affinity chromatography on glutathione-Sepharose (Amersham Pharmacia). Cell lysates containing approximately 5 g of erslips were visualized with a Nikon Microphot upright microscope with a 100ϫ objective and images were captured with an 8 bit CCD GST-BRCA2 fusion protein were mixed with 10 l glutathione-Sepharose, incubated for 3 hr at 4ЊC, and washed three times each camera driven by Signal Analytics image processing program.
